The FDA just rejected MDMA for PTSD and demanded another massive trial. They are way too slow and bureaucratic to greenlight any psychedelic this year.
Also, the advisory panel’s concerns weren’t just red tape—they hit trial design, bias, and safety monitoring. That makes a quick 2024 approval really unlikely.
